References
- Freireich E. J. Arabinosyl Cytosine: a 20-year update. J. Clin. Oncol. 1987; 5: 523–524
- Southwest Oncology Group: Cytarabine for acute leukemia in adults. Arch. Intern. Med. 1974; 133: 251
- Rudnick S., Cadman E. C., Capizzi R. L., et al. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979; 44: 1189–1193
- Herzig R. H., Wolff S. N., Lazarus H. M., et al. High dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369
- Gantin G., Brennan J. K. High-dose cytosine arabinoside for acute nonlymphocytic leukemia. Am. J. Hema-tol. 1984; 16: 5–66
- Preisler H. D., Epstein J., Barcos M., et al. Prediction of response of acute nonlymphocytic leukemia to therapy with “high dose” cytosine arabinoside. Br. J. Haematol. 1984; 58: 19–32
- Vogler R. W., Preisler H. D., Winton H. D., et al. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a leukemia inter-group study. Cancer Treat. Rep. 1986; 70: 455–459
- Kantarjian H. M., Estey E. H., Plunkett W., et al. Phase I–II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am. J. Med. 1986; 81: 387–394
- Plunkett W., Iacoboni S., Keating M. J. Cellular pharmacology and optimal therapeutic concentrations of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-β-D-arabinofuranosylcytosine. Scand. J. Haematol. 1986; 36(suppl 44)51–59
- Estey E. H., Plunkett W., Dixon D., et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987; 1: 580–583
- Plunkett W., Liliemark J. O., Adams T. M., et al. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res. 1987; 47: 3005–3011
- Keating M., Gehan E., Smith T., et al. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J. Clin. Oncol. 1987; 5: 710–721
- Baker W. J., Royer G. L., Weiss R. B. Cytarabine and neurologic toxicity. J. Clin. Oncol. 1991; 9: 679–693
- Gandhi V., Plunkett W. Modulation of arabinosylnu-cleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988; 48: 329–334
- Gandhi V., Nowak B., Keating M. J., et al. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoro-adenine in lymphocytes from patients with chronic lympho-cytic leukemia: implications for combination therapy. Blood 1989; 74: 2070–2075
- Gandhi V., Kemena A., Keating M. J., et al. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992; 52: 897–903
- Gandhi V., Estey E., Keating M. J., et al. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk. Lymph., in press
- Estey E., Kantarjian H., Plunkett W., et al. Proc. Am. Soc. Clin. Oncol. 1992; 11: 268, (abstr)